CHELSEA WAILGUM: Open Payments
NPI 1568015014 · PITTSFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,433 in 59 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $170 · 2025 $1,433
Food & beverage: $1,433
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $340 |
| Regeneron Healthcare Solutions, Inc. | 8 | $173 |
| GENZYME CORPORATION | 4 | $121 |
| Novartis Pharmaceuticals Corporation | 4 | $109 |
| GlaxoSmithKline, LLC. | 4 | $89 |
| Grifols USA, LLC | 3 | $77 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $72 |
| Lilly USA, LLC | 3 | $67 |
| CSL Behring | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
Products named: DUPIXENT, FASENRA, AIRSUPRA, TEZSPIRE, Prolastin-C Liquid, NEFFY, EBGLYSS, NUCALA.
Industry payments across MA — which companies pay providers there.
